Abstract
Lifestyle intervention prevents or delays the conversion from impaired glucose tolerance (IGT) to type 2 diabetes. However, many subjects fail to achieve and/or maintain long-term weight loss and to follow a regular exercise regimen may require pharmacologic therapy. Insulin resistance in liver, muscle and fat, along with impaired beta-cell function, plays a central role in the pathogenesis of type 2 diabetes. Insulin sensitising drugs, including metformin and the thiazolidinediones, have significantly reduced the conversion rate of IGT to type 2 diabetes in subjects in several large, well designed clinical trials. Insulin-sensitising drugs are likely to play an important role in future strategies for diabetes prevention.
Original language | English (US) |
---|---|
Pages (from-to) | S24-S40 |
Journal | British Journal of Diabetes and Vascular Disease |
Volume | 3 |
Issue number | SUPPL. 1 |
DOIs | |
State | Published - Jan 1 2003 |
Keywords
- Beta-cell dysfunction
- Impaired glucose tolerance
- Insulin resistance
- Metformin
- Thiazolidinediones
- Type 2 diabetes
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Cardiology and Cardiovascular Medicine